Johnson & Johnson (JNJ) 95.37 $JNJ
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 1 hr 3 mins ago
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.07 (+0.04), HON: 101.16 (+0.09), DAL: 47.21 (+1.25), C: 51.38 (-0.27), PSTG: 16.60 (+0.67), QSII: 12.54 (+0.11), INTC: 32.14 (-0.38), SLB: 76.36 (-0.28), JNJ: 95.37 (+0.29), T: 33.14 (-0.26), ETP: 46.39 (+0.91), JPM: 61.93 (-0.20), GWPH: 87.75 (+0.45), HSIC: 141.70 (+0.51), GLNG: 32.01 (-1.47), LNG: 53.04 (-0.25), WFC: 52.14 (-0.40), BAC: 15.58 (-0.17), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), CSX: 29.08 (-0.01), CI: 136.36 (+2.73), RDUS: 57.80 (-3.30), WBA: 85.37 (+1.09), GS: 179.19 (-1.88), VZ: 44.16 (-0.07)
Aduro Gets Milestone Payment for ADU-214's IND Submission
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 3:50PM CDT
Aduro (ADRO) announced that it has received a milestone payment from Janssen Biotech for its submitting an IND Application to the FDA for ADU-214.
JNJ: 95.37 (+0.29), ADRO: 22.06 (+0.32), ANIK: 33.46 (+0.29), NVET: 3.64 (-0.10)
4 Things Johnson & Johnson Should Address When it Reports Its Q3 Results
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 3:42PM CDT
Johnson & Johnson CEO Alex Gorsky. Source: Johnson & Johnson. If you ask me, earnings season never really "ends" in the true sense of the word. However, with fall officially here, and the calendar moving into October, we can prepare for the...
JNJ: 95.37 (+0.29)
Stocks Crawl Into the Weekend as More Earnings Loom
at The Street - Fri Oct 09, 3:01PM CDT
Stocks barely make any moves on Friday as investors wait until next week for the earnings season to crank up a notch.
BUD: 111.88 (+1.19), GE: 28.07 (+0.04), DAL: 47.21 (+1.25), C: 51.38 (-0.27), WMT: 66.69 (-0.19), BAC: 15.58 (-0.17), WFC: 52.14 (-0.40), LL: 18.84 (+2.42), INTC: 32.14 (-0.38), NFLX: 113.33 (-1.60), JNJ: 95.37 (+0.29), RT: 5.80 (-0.80), AA: 10.26 (-0.75), GS: 179.19 (-1.88), EBAY: 24.30 (+0.15), JPM: 61.93 (-0.20), MAT: 22.35 (+0.02), AAL: 42.42 (+2.68), GPS: 27.42 (-1.53), HMC: 32.72 (+0.22)
Q3 Earnings Season Preview
Sheraz Mian - Zacks Investment Research - Fri Oct 09, 2:45PM CDT
Q3 Earnings Season Preview
NFLX: 113.33 (-1.60), JNJ: 95.37 (+0.29), GE: 28.07 (+0.04), GS: 179.19 (-1.88), JPM: 61.93 (-0.20), HON: 101.16 (+0.09), C: 51.38 (-0.27), KSU: 97.95 (-0.51), BAC: 15.58 (-0.17), WFC: 52.14 (-0.40), INTC: 32.14 (-0.38), AAPL: 112.12 (+2.62), SLB: 76.36 (-0.28)
What to Expect When Johnson & Johnson (JNJ) Reports Earnings Tuesday
at The Street - Fri Oct 09, 10:33AM CDT
Johnson & Johnson (JNJ) is scheduled to release its 2015 third quarter earnings results before the market open on Tuesday.
JNJ: 95.37 (+0.29)
Johnson & Johnson (JNJ) Crosses Pivot Point Resistance at $95.58
Comtex SmarTrend(R) - Fri Oct 09, 9:34AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $94.69 today and have reached the first resistance level of $95.58. Should the shares continue to rise, the resistance pivots of $96.08 and $97.47 will be of interest.
JNJ: 95.37 (+0.29)
Johnson & Johnson starts Ebola vaccine trial in Sierra Leone
AP - Fri Oct 09, 6:01AM CDT
NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.
JNJ: 95.37 (+0.29)
Johnson & Johnson to Report Earnings Under a ‘Death Cross’
at The Street - Fri Oct 09, 4:55AM CDT
Johnson & Johnson needs a healthy weekly chart to offset a negative daily chart.
JNJ: 95.37 (+0.29)
Johnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone
PR Newswire - Fri Oct 09, 1:00AM CDT
Johnson & Johnson (NYSE: JNJ) today announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first volunteers have received their initial vaccine dose. This is the first study conducted of Janssen's Ebola prime-boost vaccine regimen in a West African country affected by the recent Ebola epidemic.
JNJ: 95.37 (+0.29)
3 Pharma Stocks With Big Margins of Safety
Brian Feroldi, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 3:43PM CDT
Healthcare stocks have had a rough past couple of months. The Vanguard Health Care ETF (VHT) , an exchange traded fund that tracks the returns of 342 stocks from the healthcare sector, is down more than 17% from its recent 52-week high, which could...
JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), VHT: 125.98 (+0.73)
Robins Kaplan LLP Named Co-Lead Counsel in Disposable Contact Lens Antitrust Litigation
Business Wire - Thu Oct 08, 10:37AM CDT
National law firm Robins Kaplan LLP announced today that it has been named co-lead counsel in antitrust litigation against the four dominant manufacturers and the largest nationwide distributor of contact lenses. As co-lead counsel, Robins Kaplan represents a proposed class of individual consumers that purchased contact lenses from retailers and eye care professionals that could number in the millions.
JNJ: 95.37 (+0.29)
5 Sector Favorites for Q3 Earnings & Their Hot ETFs
Sweta Killa - Zacks Investment Research - Thu Oct 08, 10:10AM CDT
These sector ETFs are expected to be the winners this earnings season.
DHI: 30.65 (unch), JNJ: 95.37 (+0.29), LEN: 51.33 (+0.26), JPM: 61.93 (-0.20), PFE: 33.24 (+0.15), ITB: 27.85 (-0.03), CARZ: 36.26 (+0.16), WFC: 52.14 (-0.40), BRK.B: 133.03 (-0.72), XLF: 23.24 (-0.15), IYT: 148.36 (+1.15), XLV: 68.44 (+0.31)
Anti-fatigue mat company excited to partner with Google's Small Business Minority Supplier Program
PR Newswire - Thu Oct 08, 6:20AM CDT
Layne Resource Group recently accepted Google's invitation to participate in its innovative Small Business Minority Supplier Program -- a program that assists small diverse companies with the expansion and growth of their business presences online.
JNJ: 95.37 (+0.29)
Watch for Johnson & Johnson to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Wed Oct 07, 3:49PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $93.44 to a high of $95.42. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $94.82 on volume of 9.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 95.37 (+0.29)
Global Diabetes Care Devices Market Outlook 2015-2020 - Market is Expected to Grow at a CAGR of 5.2%
M2 - Wed Oct 07, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb8dxs/global_diabetes) has announced the addition of the "Global Diabetes Care Devices Market Outlook: 2015-2020" report to their offering. The global diabetes care devices market is expected to grow at a CAGR of 5.2% from 2015 to 2020 to reach $24.6 billion by 2020 This market is mainly driven by increasing prevalence of diabetes, technological advancements, rise in obese population, sedentary lifestyle and improper diet, and increasing need for faster and safer diagnosis and treatment of diabetes. Furthermore, huge investments by the market leaders and foraying of new companies into this market, wide scope of penetration in untapped and emerging markets, and rising awareness among people about diabetes care are also accelerating the growth of this market. However, high cost associated with diagnosis and treatment, reimbursement issues for new technologies, lack of awareness, strict regulatory obligations, and high cost of diabetic food hinders the growth of this market to some extent. The research report on the diabetes care devices market provides comprehensive analysis of the global market with a country level analysis and helps in understanding the driving forces for the growth of this market. The report also provides analysis of major product segments such as diabetes control solutions, diabetes monitoring devices, and insulin delivery devices. The diabetes monitoring devices segment further sub-segmented into continuous blood glucose monitoring devices, test strips, lancets, and hemoglobin A1c (HbA1c) testing kits. The insulin delivery devices further sub-segmented into insulin syringes, insulin pens, insulin pumps, and insulin injectors. Key Topics Covered: 1 Introduction to Diabetes Care Devices Market 2 Executive Summary 3 Market Insights 4 Global Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Product Type 5 Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Geography 6 Global Diabetes Care Devices Market- Competitive Landscape 7 Company Profiles - ARKRAY Inc. - Abbott Laboratories - Bayer HealthCare AG - Becton, Dickinson and Company - Dexcom, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Medtronic, Inc. - Novo Nordisk A/S - Sanofi S.A - Tandem Diabetes Care, Inc - Terumo Corporation - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/jb...l_diabetes
JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), NVO: 54.61 (-0.12), MDT: 72.60 (+0.55), LLY: 86.14 (+2.37)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RCPT: 231.96 (-0.03), TEVA: 58.96 (-0.28), REGN: 503.92 (+12.71), CELG: 117.38 (-0.59)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 1 hr 3 mins ago
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.07 (+0.04), HON: 101.16 (+0.09), DAL: 47.21 (+1.25), C: 51.38 (-0.27), PSTG: 16.60 (+0.67), QSII: 12.54 (+0.11), INTC: 32.14 (-0.38), SLB: 76.36 (-0.28), JNJ: 95.37 (+0.29), T: 33.14 (-0.26), ETP: 46.39 (+0.91), JPM: 61.93 (-0.20), GWPH: 87.75 (+0.45), HSIC: 141.70 (+0.51), GLNG: 32.01 (-1.47), LNG: 53.04 (-0.25), WFC: 52.14 (-0.40), BAC: 15.58 (-0.17), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), CSX: 29.08 (-0.01), CI: 136.36 (+2.73), RDUS: 57.80 (-3.30), WBA: 85.37 (+1.09), GS: 179.19 (-1.88), VZ: 44.16 (-0.07)
Aduro Gets Milestone Payment for ADU-214's IND Submission
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 3:50PM CDT
Aduro (ADRO) announced that it has received a milestone payment from Janssen Biotech for its submitting an IND Application to the FDA for ADU-214.
JNJ: 95.37 (+0.29), ADRO: 22.06 (+0.32), ANIK: 33.46 (+0.29), NVET: 3.64 (-0.10)
4 Things Johnson & Johnson Should Address When it Reports Its Q3 Results
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 3:42PM CDT
Johnson & Johnson CEO Alex Gorsky. Source: Johnson & Johnson. If you ask me, earnings season never really "ends" in the true sense of the word. However, with fall officially here, and the calendar moving into October, we can prepare for the...
JNJ: 95.37 (+0.29)
Stocks Crawl Into the Weekend as More Earnings Loom
at The Street - Fri Oct 09, 3:01PM CDT
Stocks barely make any moves on Friday as investors wait until next week for the earnings season to crank up a notch.
BUD: 111.88 (+1.19), GE: 28.07 (+0.04), DAL: 47.21 (+1.25), C: 51.38 (-0.27), WMT: 66.69 (-0.19), BAC: 15.58 (-0.17), WFC: 52.14 (-0.40), LL: 18.84 (+2.42), INTC: 32.14 (-0.38), NFLX: 113.33 (-1.60), JNJ: 95.37 (+0.29), RT: 5.80 (-0.80), AA: 10.26 (-0.75), GS: 179.19 (-1.88), EBAY: 24.30 (+0.15), JPM: 61.93 (-0.20), MAT: 22.35 (+0.02), AAL: 42.42 (+2.68), GPS: 27.42 (-1.53), HMC: 32.72 (+0.22)
Q3 Earnings Season Preview
Sheraz Mian - Zacks Investment Research - Fri Oct 09, 2:45PM CDT
Q3 Earnings Season Preview
NFLX: 113.33 (-1.60), JNJ: 95.37 (+0.29), GE: 28.07 (+0.04), GS: 179.19 (-1.88), JPM: 61.93 (-0.20), HON: 101.16 (+0.09), C: 51.38 (-0.27), KSU: 97.95 (-0.51), BAC: 15.58 (-0.17), WFC: 52.14 (-0.40), INTC: 32.14 (-0.38), AAPL: 112.12 (+2.62), SLB: 76.36 (-0.28)
What to Expect When Johnson & Johnson (JNJ) Reports Earnings Tuesday
at The Street - Fri Oct 09, 10:33AM CDT
Johnson & Johnson (JNJ) is scheduled to release its 2015 third quarter earnings results before the market open on Tuesday.
JNJ: 95.37 (+0.29)
Johnson & Johnson (JNJ) Crosses Pivot Point Resistance at $95.58
Comtex SmarTrend(R) - Fri Oct 09, 9:34AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $94.69 today and have reached the first resistance level of $95.58. Should the shares continue to rise, the resistance pivots of $96.08 and $97.47 will be of interest.
JNJ: 95.37 (+0.29)
Johnson & Johnson starts Ebola vaccine trial in Sierra Leone
AP - Fri Oct 09, 6:01AM CDT
NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.
JNJ: 95.37 (+0.29)
Johnson & Johnson to Report Earnings Under a ‘Death Cross’
at The Street - Fri Oct 09, 4:55AM CDT
Johnson & Johnson needs a healthy weekly chart to offset a negative daily chart.
JNJ: 95.37 (+0.29)
Johnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone
PR Newswire - Fri Oct 09, 1:00AM CDT
Johnson & Johnson (NYSE: JNJ) today announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first volunteers have received their initial vaccine dose. This is the first study conducted of Janssen's Ebola prime-boost vaccine regimen in a West African country affected by the recent Ebola epidemic.
JNJ: 95.37 (+0.29)
3 Pharma Stocks With Big Margins of Safety
Brian Feroldi, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Thu Oct 08, 3:43PM CDT
Healthcare stocks have had a rough past couple of months. The Vanguard Health Care ETF (VHT) , an exchange traded fund that tracks the returns of 342 stocks from the healthcare sector, is down more than 17% from its recent 52-week high, which could...
JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), ABBV: 55.64 (-0.40), VHT: 125.98 (+0.73)
Robins Kaplan LLP Named Co-Lead Counsel in Disposable Contact Lens Antitrust Litigation
Business Wire - Thu Oct 08, 10:37AM CDT
National law firm Robins Kaplan LLP announced today that it has been named co-lead counsel in antitrust litigation against the four dominant manufacturers and the largest nationwide distributor of contact lenses. As co-lead counsel, Robins Kaplan represents a proposed class of individual consumers that purchased contact lenses from retailers and eye care professionals that could number in the millions.
JNJ: 95.37 (+0.29)
5 Sector Favorites for Q3 Earnings & Their Hot ETFs
Sweta Killa - Zacks Investment Research - Thu Oct 08, 10:10AM CDT
These sector ETFs are expected to be the winners this earnings season.
DHI: 30.65 (unch), JNJ: 95.37 (+0.29), LEN: 51.33 (+0.26), JPM: 61.93 (-0.20), PFE: 33.24 (+0.15), ITB: 27.85 (-0.03), CARZ: 36.26 (+0.16), WFC: 52.14 (-0.40), BRK.B: 133.03 (-0.72), XLF: 23.24 (-0.15), IYT: 148.36 (+1.15), XLV: 68.44 (+0.31)
Anti-fatigue mat company excited to partner with Google's Small Business Minority Supplier Program
PR Newswire - Thu Oct 08, 6:20AM CDT
Layne Resource Group recently accepted Google's invitation to participate in its innovative Small Business Minority Supplier Program -- a program that assists small diverse companies with the expansion and growth of their business presences online.
JNJ: 95.37 (+0.29)
Watch for Johnson & Johnson to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Wed Oct 07, 3:49PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $93.44 to a high of $95.42. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $94.82 on volume of 9.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 95.37 (+0.29)
Global Diabetes Care Devices Market Outlook 2015-2020 - Market is Expected to Grow at a CAGR of 5.2%
M2 - Wed Oct 07, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb8dxs/global_diabetes) has announced the addition of the "Global Diabetes Care Devices Market Outlook: 2015-2020" report to their offering. The global diabetes care devices market is expected to grow at a CAGR of 5.2% from 2015 to 2020 to reach $24.6 billion by 2020 This market is mainly driven by increasing prevalence of diabetes, technological advancements, rise in obese population, sedentary lifestyle and improper diet, and increasing need for faster and safer diagnosis and treatment of diabetes. Furthermore, huge investments by the market leaders and foraying of new companies into this market, wide scope of penetration in untapped and emerging markets, and rising awareness among people about diabetes care are also accelerating the growth of this market. However, high cost associated with diagnosis and treatment, reimbursement issues for new technologies, lack of awareness, strict regulatory obligations, and high cost of diabetic food hinders the growth of this market to some extent. The research report on the diabetes care devices market provides comprehensive analysis of the global market with a country level analysis and helps in understanding the driving forces for the growth of this market. The report also provides analysis of major product segments such as diabetes control solutions, diabetes monitoring devices, and insulin delivery devices. The diabetes monitoring devices segment further sub-segmented into continuous blood glucose monitoring devices, test strips, lancets, and hemoglobin A1c (HbA1c) testing kits. The insulin delivery devices further sub-segmented into insulin syringes, insulin pens, insulin pumps, and insulin injectors. Key Topics Covered: 1 Introduction to Diabetes Care Devices Market 2 Executive Summary 3 Market Insights 4 Global Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Product Type 5 Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Geography 6 Global Diabetes Care Devices Market- Competitive Landscape 7 Company Profiles - ARKRAY Inc. - Abbott Laboratories - Bayer HealthCare AG - Becton, Dickinson and Company - Dexcom, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Medtronic, Inc. - Novo Nordisk A/S - Sanofi S.A - Tandem Diabetes Care, Inc - Terumo Corporation - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/jb...l_diabetes
JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), NVO: 54.61 (-0.12), MDT: 72.60 (+0.55), LLY: 86.14 (+2.37)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 274.84 (-1.32), JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), RCPT: 231.96 (-0.03), TEVA: 58.96 (-0.28), REGN: 503.92 (+12.71), CELG: 117.38 (-0.59)
